---
title: FCF Healthcare & Life Sciences Venture Capital Monitor - Europe - 02/2026 published
description: "FCF Fox Corporate Finance GmbH is pleased to publish the new \"FCF Healthcare & Life Sciences Venture Capital Monitor - Europe 02/2026\". The FCF Healthcare & Life Sciences Venture Capital Monitor - Europe is a ... Read more"
---

[Research ](https://www.fcf.de/en/resources/research)

# [FCF Healthcare & Life Sciences Venture Capital Monitor - Europe - 02/2026 published](https://www.fcf.de/en/resources/research/fcf-healthcare-life-sciences-venture-capital-monitor-europa-02/2026-veröffentlicht)

 Written by [FCF Healthcare & Life Sciences](https://www.fcf.de/en/resources/research/author/fcf-healthcare-life-sciences) | May 5, 2026 12:01:44 PM

FCF Fox Corporate Finance GmbH is pleased to publish the new "**FCF Healthcare & Life Sciences Venture Capital Monitor - Europe 02/2026**".

The **FCF Healthcare** & Life **Sciences Venture Capital Monitor - Europe** is a monthly overview of financing trends in the venture capital sector with a focus on European healthcare & life sciences companies.

As of the end of February 2026, we identified the following current VC trends in Europe:

- Total Healthcare & Life Sciences funding reached EUR 1,456m (-51% vs. 2025), which represents about half of the volume of the same period in 2025
- Biotech/Pharma received 40% of the total investment volume (EUR 576m), with ophthalmology being the leading indication (47%)
- In February, Immutrin (United Kingdom) secured the highest transaction volume with EUR 75m, followed by NEUROMARK (United States) with EUR 63m and Dawn Health (Denmark) with EUR 33m
- EQT Life Sciences (Netherlands) is the most active investor (by deal volume in 2026), followed by F-Prime Capital (United States) and Sofinnova Partners (France)

So far in 2026, we see fewer large-ticket deals, which explains the steep decline in funding volume. We are only two months into 2026, so the market could still recover.

To read the full report, click [here](https://www.fcf.de/resources/research/download-request-fcf-healthcare-life-sciences-research-series-europe?hsLang=en).<https://www.fcf.de/de/unser-team/johannes-link/?hsLang=en>

**

 

[View full post](https://www.fcf.de/en/resources/research/fcf-healthcare-life-sciences-venture-capital-monitor-europa-02/2026-veröffentlicht)

```json
{
  "@context" : "http://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "FCF Healthcare & Life Sciences"
  },
  "dateModified" : "2026-05-05T12:01:44.946Z",
  "datePublished" : "2026-05-05T12:01:44Z",
  "headline" : "FCF Healthcare & Life Sciences Venture Capital Monitor – Europe – February 2026 Published",
  "image" : {
    "@type" : "ImageObject",
    "height" : 2666,
    "url" : "https://145785926.fs1.hubspotusercontent-eu1.net/hubfs/145785926/Website/Ressourcen/Healthcare_EU-Monitor_Shutterstock_2360267017_reduziert%20%281%29.jpeg",
    "width" : 4000
  },
  "mainEntityOfPage" : "https://www.fcf.de/en/resources/research/fcf-healthcare-life-sciences-venture-capital-monitor-europa-02/2026-veröffentlicht",
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "height" : 60,
      "url" : "/hs/hsstatic/content_shared_assets/static-1.4092/img/default-amp-logo.png",
      "width" : 60
    },
    "name" : "Research"
  }
}
```